Literature DB >> 9429843

Cardioprotection by ACE inhibitors in myocardial ischaemia/reperfusion. The importance of bradykinin.

G Heusch1, J Rose, T Ehring.   

Abstract

Myocardial ischaemia, when severe and sustained for more than 40 minutes, results in irreversible damage, i.e. myocardial infarction. However, with early reperfusion, damage is reversible. Complete recovery of contractile function requires some time, despite fully or almost fully restored blood flow. This phenomenon has been termed myocardial stunning. There is experimental evidence showing that angiotensin converting enzyme (ACE) inhibitors limit the development of infarct size, reduce the incidence of ischaemic and reperfusion arrhythmias, and enhance the recovery of contractile function of stunned myocardium. These cardioprotective effects of ACE inhibitors are mediated by an attenuated degradation of bradykinin.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9429843     DOI: 10.2165/00003495-199700545-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  98 in total

1.  Cardiac reperfusion damage prevented by a nitroxide free radical.

Authors:  D Gelvan; P Saltman; S R Powell
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

2.  [Captopril in acute myocardial infarct: its effect on infarct size and arrhythmias].

Authors:  W D Bussmann; G Micke; R Hildenbrand; H Klepzig
Journal:  Dtsch Med Wochenschr       Date:  1992-04-24       Impact factor: 0.628

3.  Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: a comparison of captopril, enalapril, and HOE 498.

Authors:  W H van Gilst; P A de Graeff; H Wesseling; C D de Langen
Journal:  J Cardiovasc Pharmacol       Date:  1986 Jul-Aug       Impact factor: 3.105

Review 4.  Stunned myocardium and the attenuation of stunning by calcium antagonists.

Authors:  T Ehring; G Heusch
Journal:  Am J Cardiol       Date:  1995-04-27       Impact factor: 2.778

5.  The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators.

Authors:  E Ambrosioni; C Borghi; B Magnani
Journal:  N Engl J Med       Date:  1995-01-12       Impact factor: 91.245

6.  Angiotensin-converting enzyme inhibition limits dysfunction in adjacent noninfarcted regions during left ventricular remodeling.

Authors:  C M Kramer; V A Ferrari; W J Rogers; T M Theobald; M L Nance; L Axel; N Reichek
Journal:  J Am Coll Cardiol       Date:  1996-01       Impact factor: 24.094

7.  Protection of the ischemic myocardium by the converting-enzyme inhibitor zofenopril: insight into its mechanism of action.

Authors:  R Ferrari; A Cargnoni; S Curello; C Ceconi; A Boraso; O Visioli
Journal:  J Cardiovasc Pharmacol       Date:  1992       Impact factor: 3.105

8.  Interactions between coronary occlusion and the renin-angiotensin system in the dog.

Authors:  G Ertl; R W Alexander; R A Kloner
Journal:  Basic Res Cardiol       Date:  1983 Sep-Oct       Impact factor: 17.165

9.  GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico.

Authors: 
Journal:  Lancet       Date:  1994-05-07       Impact factor: 79.321

10.  Influence of local converting enzyme inhibition on angiotensin and bradykinin effects in ischemic rat hearts.

Authors:  W Linz; B A Schölkens
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

View more
  5 in total

Review 1.  Protecting the ischaemic and reperfused myocardium in acute myocardial infarction: distant dream or near reality?

Authors:  D M Yellon; G F Baxter
Journal:  Heart       Date:  2000-04       Impact factor: 5.994

Review 2.  Role of bradykinin in preconditioning and protection of the ischaemic myocardium.

Authors:  G F Baxter; Z Ebrahim
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

3.  Apstatin, a selective inhibitor of aminopeptidase P, reduces myocardial infarct size by a kinin-dependent pathway.

Authors:  S Wolfrum; G Richardt; P Dominiak; H A Katus; A Dendorfer
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

Review 4.  Cardioprotective actions of peptide hormones in myocardial ischemia.

Authors:  Dwaine S Burley; Shabaz A Hamid; Gary F Baxter
Journal:  Heart Fail Rev       Date:  2007-12       Impact factor: 4.214

5.  Kinin B2 receptor is not involved in enalapril-induced apoptosis and regression of hypertrophy in spontaneously hypertensive rat aorta: possible role of B1 receptor.

Authors:  David Duguay; Shant Der Sarkissian; Rémi Kouz; Brice Ongali; Réjean Couture; Denis deBlois
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.